Evolution of a Pulmonary Insulin Delivery System ( Exubera) for Patients With Diabetes

Priscilla A. Hollander, MD


March 05, 2007


Reducing the barriers to insulin therapy has the potential to improve clinical outcomes and quality of life in patients with diabetes. The key barriers to the adoption of insulin therapy are patient- and physician-related barriers, which include fear and anxiety about injecting insulin, concerns about side effects, and personal health beliefs with regard to the use of insulin. New treatment approaches, such as inhaled insulin, are aimed toward eliminating some of these barriers to the currently available regimens.

Several inhaled insulin systems are currently being developed for the treatment of patients with type 1 or type 2 diabetes, of which INH is the first and only system approved for use in the United States and in Europe. Clinical studies have shown that INH consistently improves glycemic control, whether added to longer-acting SC insulin regimens in patients with type 1 or type 2 diabetes or used to supplement or replace OA therapy in patients with type 2 diabetes. INH has also demonstrated long-term safety and tolerability, with a risk for hypoglycemia similar to that of SC insulin, and no clinically important changes in pulmonary function were noted. Patients treated with INH in clinical studies reported high levels of satisfaction with treatment, and many patients with diabetes choose inhaled insulin when it is offered as a treatment option. These findings, taken together, suggest that INH provides an important new approach in the treatment of diabetes -- one that offers additional choices to patients, and consequently, may improve diabetes control and the lives of many patients with diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.